Sugi Predict

Sugi Predict / Compounds / SCHEMBL183994

SCHEMBL183994

SCHEMBL183994

COC(=O)c1cc(OCc2ccccc2)cc(C(=O)OC)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.70
▸ HPGD P15428 1/20 0.70
▸ MEN1 O00255 3/20 0.66
▸ KMT2A Q03164 3/20 0.66
▸ MAOB P27338 2/20 0.59
▸ NR4A2 P43354 2/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ SMPD1 P17405 1/20 0.56
▸ MRGPRX4 Q96LA9 2/20 0.55
▸ NR4A1 P22736 1/20 0.54
▸ NR4A3 Q92570 1/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ PTPN1 P18031 1/20 0.54
▸ MAPT P10636 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ PARP10 Q53GL7 1/20 0.51
▸ SRD5A2 P31213 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391547 0.97 MEN1 (0.71) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL3129603 0.95 MEN1 (0.74) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL14345811 0.93 LMNA (0.62) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL340311 0.92 LMNA (0.65) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL29475634 0.92 LMNA (0.69) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL29788280 0.92 LMNA (0.65) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL90412 0.92 LMNA (0.69) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL8900334 0.91 SMPD1 (0.60) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL7362723 0.91 HPGD (0.63) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL7420476 0.90 LMNA (0.62) LMNAHPGDMEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778612-B1 PHOSPHATE DERIVATIVES AND USE THEREOF SHANGHAI SHENGYUE PHARMACEUTICAL TECH CO LTD (CN) 2025-02-12 — — EP disclosed
CN-110317230-B Phosphate derivatives and use thereof 上海昇悦医药科技有限公司 2023-11-07 — — CN disclosed
EP-3778612-A1 PHOSPHATE DERIVATIVES AND USE THEREOF Zhu, Qing (CN) 2021-02-17 — — EP disclosed
EP-3778612-A1 PHOSPHATE DERIVATIVES AND USE THEREOF Zhu, Qing (CN) 2021-02-17 — — EP disclosed
US-20210030773-A1 PHOSPHATE DERIVATIVES AND USE THEREOF Shanghai Shengyue Pharmaceutical Technology Co., Ltd. (CN) 2021-02-04 — — US disclosed
WO-2019184866-A1 PHOSPHATE DERIVATIVES AND USE THEREOF 朱青 2019-10-03 — — WO disclosed
WO-2019184866-A1 PHOSPHATE DERIVATIVES AND USE THEREOF 朱青 2019-10-03 — — WO disclosed
WO-2017154991-A1 TEMPERATURE-RESPONSIVE COMPOUND 国立大学法人九州大学 2017-09-14 — — WO disclosed
WO-2016001452-A1 COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED Universität Zürich (CH) 2016-01-07 — — WO disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 — — US disclosed
EP-1567488-B1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LTD (GB) 2007-02-21 — — EP disclosed
WO-2006040568-A1 QUINOXALINES AS B RAF INHIBITORS ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2006024834-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS ASTRAZENECA AB (SE) 2006-03-09 — — WO disclosed
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-02-02 — — US disclosed
WO-2006003378-A1 AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT ASTRAZENECA AB (SE) 2006-01-12 — — WO disclosed
EP-1567488-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2005-08-31 — — EP disclosed
US-6806395-B2 FOR PRODUCING 3,5- DIISOPROPYLPHENOL OR A SIMILAR COMPOUND, WHICH SERVES AS AN INTERMEDIATE FOR PRODUCING ANTI-INFLAMMATORY AGENTS, PESTICIDES, ETC. KOWA CO., LTD. (JP) 2004-10-19 — — US disclosed
WO-2004050619-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2004-06-17 — — WO disclosed
US-20040044255-A1 Process for preparation of 3,5-bisalkylphenols KOWA CO., LTD. (JP) 2004-03-04 — — US disclosed
EP-1319646-A1 PROCESS FOR PREPARATION OF 3,5-BISALKYLPHENOLS Kowa Co., Ltd. (JP) 2003-06-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease BACE2, PSEN2, BACE1 LMNA 1062/4885HPGD 2131/4885MEN1 586/4885
US-20210030773-A1 PHOSPHATE DERIVATIVES AND USE THEREOF CXCL12, MIF, FGF23 LMNA 4000/4885HPGD 1140/4885MEN1 619/4885
US-20040044255-A1 Process for preparation of 3,5-bisalkylphenols ACSL3, HACL2, ARL1 LMNA 2714/4885HPGD 4105/4885MEN1 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.